Organization | Jacobs Neurological Institute

Jacobs Neurological Institute Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2009

NCT00986960

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (8)

acetylsalicylic acid (aspirin) (1 trial)

aggrenox (1 trial)

alteplase (Activase) (1 trial)

atorvastatin (lipitor) (1 trial)

clopidogrel (plavix) (1 trial)

corticotropin (acthar) (1 trial)

rosuvastatin (crestor) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Stroke (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial APIs: 8